These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 6329512)

  • 1. Screening procedure for the development of mammary tumour-inhibiting anti-oestrogens.
    Hartmann RW
    Cancer Treat Rev; 1984 Mar; 11 Suppl A():155-61. PubMed ID: 6329512
    [No Abstract]   [Full Text] [Related]  

  • 2. Ring-substituted 1,2-dialkylated 1,2-bis(hydroxyphenyl)ethanes. 3. Synthesis, estrogen receptor binding affinity, and evaluation of antiestrogenic and mammary tumor inhibiting activity of 2,2'-disubstituted butestrols and 6,6'-disubstituted metabutestrols.
    Hartmann RW; Heindl A; Schwarz W; Schönenberger H
    J Med Chem; 1984 Jul; 27(7):819-24. PubMed ID: 6330356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential antiestrogens. Synthesis and evaluation of mammary tumor inhibiting activity of 1,2-dialkyl-1,2-bis(3'-hydroxyphenyl)ethanes.
    Hartmann RW; Buchborn H; Kranzfelder G; Schönenberger H; Bogden A
    J Med Chem; 1981 Oct; 24(10):1192-7. PubMed ID: 6276542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ring-substituted 1,1,2,2-tetraalkylated 1,2-bis(hydroxyphenyl)ethanes. 4. Synthesis, estrogen receptor binding affinity, and evaluation of antiestrogenic and mammary tumor inhibiting activity of symmetrically disubstituted 1,1,2,2-tetramethyl-1,2-bis(hydroxyphenyl)ethanes.
    Hartmann RW; Schwarz W; Heindl A; Schönenberger H
    J Med Chem; 1985 Sep; 28(9):1295-301. PubMed ID: 2993619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of new drugs for endocrine tumour chemotherapy.
    von Angerer E
    Cancer Treat Rev; 1984 Mar; 11 Suppl A():147-53. PubMed ID: 6547370
    [No Abstract]   [Full Text] [Related]  

  • 6. Antiestrogens. Synthesis and evaluation of mammary tumor inhibiting activity of 1,1,2,2-tetraalkyl-1,2 -diphenylethanes.
    Hartmann RW; Kranzfelder G; von Angerer E; Schönenberger H
    J Med Chem; 1980 Aug; 23(8):841-8. PubMed ID: 7401112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 3,4-bis(3'-hydroxyphenyl)hexane--a new mammary tumor-inhibiting compound.
    Kranzfelder G; Hartmann RW; von Angerer E; Schönenberger H; Bogden AE
    J Cancer Res Clin Oncol; 1982; 103(2):165-80. PubMed ID: 6284766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of alkyl-chain fluorination on the action of mammary tumor inhibiting 2,3-bis(hydroxyphenyl)butanes and 2,3-bis(hydroxyphenyl)but-2-enes.
    Hartmann RW; Heindl A; Schneider MR; Schönenberger H
    J Med Chem; 1986 Mar; 29(3):322-8. PubMed ID: 3005573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Steroid hormone receptors in mammary carcinoma: the effect of tamoxifen.
    Koenders AJ; Beex LV; Geurts-Moespot J; Benraad TJ
    Eur J Cancer (1965); 1980; Suppl 1():63-6. PubMed ID: 7318871
    [No Abstract]   [Full Text] [Related]  

  • 10. 2-Phenylindoles. Effect of N-benzylation on estrogen receptor affinity, estrogenic properties, and mammary tumor inhibiting activity.
    von Angerer E; Strohmeier J
    J Med Chem; 1987 Jan; 30(1):131-6. PubMed ID: 3806590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytotoxic ester derivatives of the mammary tumor inhibiting antiestrogen 2,3-bis(2-fluoro-4-hydroxyphenyl)-2,3-dimethylbutane.
    Schwarz W; Hartmann RW; Engel J; Schneider MR; Schönenberger H
    Arch Pharm (Weinheim); 1990 Feb; 323(2):121-4. PubMed ID: 2159273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis, receptor binding, and target-tissue uptake of carbon-11 labeled carbamate derivatives of estradiol and hexestrol.
    Ouellet R; Rousseau J; Brasseur N; van Lier JE; Diksic M; Westera G
    J Med Chem; 1984 Apr; 27(4):509-13. PubMed ID: 6323712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative antioestrogen action in experimental breast cancer.
    Jordan VC
    Adv Exp Med Biol; 1981; 138():165-78. PubMed ID: 6805259
    [No Abstract]   [Full Text] [Related]  

  • 14. Antitumor activities and estrogen receptor interactions of the metabolites of the antiestrogens C1628 and U23,469 in the 7,12-dimethylbenz(a)anthracene-induced rat mammary tumor system.
    Rorke EA; Katzenellenbogen BS
    Cancer Res; 1981 Apr; 41(4):1257-62. PubMed ID: 6783294
    [No Abstract]   [Full Text] [Related]  

  • 15. Steroid receptors in breast tumors--current status.
    McGuire WL; Zava DT; Horwitz KB; Chamness GC
    Curr Top Exp Endocrinol; 1978; 3():93-129. PubMed ID: 350504
    [No Abstract]   [Full Text] [Related]  

  • 16. Anti-oestrogens and breast cancer.
    Terenius L
    Eur J Cancer (1965); 1971 Feb; 7(1):57-64. PubMed ID: 5576729
    [No Abstract]   [Full Text] [Related]  

  • 17. Benzo[a]carbazole derivatives. Synthesis, estrogen receptor binding affinities, and mammary tumor inhibiting activity.
    von Angerer E; Prekajac J
    J Med Chem; 1986 Mar; 29(3):380-6. PubMed ID: 3950918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Receptor-binding radiopharmaceuticals for imaging breast tumors: estrogen-receptor interactions and selectivity of tissue uptake of halogenated estrogen analogs.
    Katzenellenbogen JA; Carlson KE; Heiman DF; Goswami R
    J Nucl Med; 1980 Jun; 21(6):550-8. PubMed ID: 6247466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of hexestrol, medroxyprogesterone acetate and chlormadinone acetate on 7, 12-dimethylbenz [a] anthracene-induced rat mammary cancer in relation to estrogen receptor.
    Tominaga T; Kitamura M; Saito T; Itoh I
    Gan; 1981 Aug; 72(4):604-9. PubMed ID: 6171473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platinum compounds with estrogen receptor affinity.
    Bednarski PJ; Gust R; Spruss T; Knebel N; Otto A; Farbel M; Koop R; Holler E; von Angerer E; Schönenberger H
    Cancer Treat Rev; 1990 Sep; 17(2-3):221-31. PubMed ID: 2272037
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.